ATAI Q2 net loss $27.7M; BPL-003 Phase 2b meets endpoints, Beckley combo on track

ATAI Life Sciences N.V.

2025-Q2 EPS reported -$0.29 revenue$2,274,000

Net loss $27.7M for Q2 2025 vs $57.3M Q2 2024; cash & short-term securities $95.9M as of June 30, 2025.
BPL-003 Phase 2b in TRD met primary and all key secondary endpoints; 8 mg dose selected for Phase 3; OLE data expected Q3 2025.
Planned strategic combination with Beckley Psytech expected to proceed to shareholder vote in Q4 2025; cash runway into H2 2027.
VLS-01 Phase 2 topline delayed to H2 2026 due to slow enrollment; EMP-01 Phase 2 topline expected Q1 2026.
Inidascamine Phase 2b missed primary endpoint; Recognify evaluating options; ATAI focusing on psychedelic pipeline.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.